Not Just a Laughing Matter: Disastrous Ending of Recreational Use of Laughing Gas

Min Jeoung Kim1, Min Chul Oh2,3, Dong Ah Shin1,3

1Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea
2Department of Neurosurgery, Mediheal Neurosurgery Clinic, Seoul, Republic of Korea
3Department of Neurosurgery, Yonsei Spine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea

Nitrous oxide (N2O) is an established and widely used anesthetic gas that is also quite commonly misused for recreational purposes, due to its wide commercial availability. Overexposure can cause demyelination and eventual gliosis, within both the central and the peripheral nervous system. Here we present a patient with N2O-induced myelopathy following 3 months of recreational use. Despite its recognized neurotoxicity, the recreational abuse of N2O is increasing and represents a major public health problem. The problem is however under-recognized and under-reported. We hope to issue a warning, raise public awareness, and initiate further research to prevent N2O abuse.

Key Words: Nitrous oxide; Myelopathy; Public health

INTRODUCTION

Nitrous oxide (N2O) gas traditionally used for surgical and dental procedures is now available in grocery stores in the Republic of Korea. This gas is sometimes called “whippets” (after the containers it is sold in), “laughing gas”, or the “epiphany drug”. Inhalation results in almost immediate psychotropic effects including euphoria, giggling, distortion of sound perception, and mild hallucinations. It has therefore been gaining popularity in recent years, especially among young people in nightclubs, and is considered a relatively innocuous substance. In fact, since Humphrey Davy reported the euphoric effects following self-administration of N2O in 17991, it has become the 7th most commonly used recreational drug worldwide and 8th most commonly used substance in the UK, according to the Global Drug Survey 20162,3, and its recreational use in the Republic of Korea has similarly increased in recent years (Table 1). While most N2O users are not aware of the harmful effects of this gas, multiple and repetitive inhalation is known to cause subacute degeneration of the spinal cord by inactivation of active vitamin B12, which leads to serious and fatal neurologic deficits4,5. Here, we report a case of a 25-year-old man who developed myelopathy and peripheral neuropathy following 3 months of recreational N2O use. We would like to raise awareness and emphasize the importance of proper management of such cases, to improve public health management, medically and socially.

CASE REPORT

Informed consent for publication of clinical data was obtained from the patient.

A 25-year-old man was admitted to our outpatient clinic, complaining of progressive quadriplegia for 3 days. He inhaled nitrous oxide gas all day for one month, at least 100 of balloon per day at nightclub. There is no neurological deficit when he started to use the gas. He could walk only a few steps with assistance. Cranial nerve examination was normal. Muscle strength was reduced to grade 4 on the Medical Research Council Scale, and he showed areflexia, ataxic, and steppage gait. On
sensory examination, proprioception and his vibratory sense were remarkably intact, but the patient’s light touch sensation, especially in the upper extremities, was impaired.

1. Radiologic examination

The patient’s brain magnetic resonance imaging (MRI) findings were normal. Initial MRI of the whole spine showed high signal intensity on T2-weighted images in the dorsal columns of the cervical spine extending from C2 to C6, consistent with subacute degeneration of the spinal cord (Fig. 1), and suspicious thoracic arteriovenous malformations (AVM) in thoracic lesions. The initial diagnosis was cervical myelopathy due to N2O abuse or secondary to thoracic AVM. During laboratory and electromyographic examinations, the patient’s lower leg weakness was found to have worsened. A follow-up cervical MRI showed more prominent and enlarged T2 signal intensity extending to C1 (Fig. 2). The patient’s digital subtraction angiography (DSA) of the spinal cord was normal. The patient was treated with injections of 20 mg dextrose (Intravenously administered, 10 mg twice daily) and 1,000 μg/day vitamin B12.

2. Laboratory examination

Most laboratory tests were within the reference range, except for decreased serum levels of vitamin B12 149 pg/mL (reference range: 250-900 pg/mL). Serum folate and copper levels were normal. Serologic tests for syphilis, Epstein-Barr virus, cytomegalovirus, and human immunodeficiency virus antibodies were negative. The serum and urine homocysteine was not proceeded. Results of cerebrospinal fluid exams were also within the reference range (no RBC, no WBC, protein: 44.1 mg/dL, glucose: 57 mg/dL).

3. Electromyographic examination (EMG)

Nerve conduction studies and electromyography showed a mild polyneuropathy with mixed axonal and demyelinating features.

Based on his history of N2O inhalation, clinical features, and neuroimaging findings, a diagnosis of myelopathy secondary to N2O intoxication was made. The patient was treated with injections of 1,000 μg/day vitamin B12 daily for 7 days, followed by 1,000 μg orally weekly. One week later, although the tingling sensations and numbness in all extremities showed no improvement, his motor and lower extremities ataxia had rapidly improved.

DISCUSSION

N2O has been used without any serious noticed or published side effects, and has been regarded innocuous, until Lassen and colleagues first reported on its toxicity in 19566). This led to a thorough discussion on whether N2O should still be used in anesthesia in the early 1980s.

N2O toxicity can cause sensory predominant myeloneuropathy similar to subacute combined degeneration (SCD) caused by vitamin B12 deficiency. The related neuropathy is symmetrical and affects the legs more than the arms. It begins with paresthesia and ataxia associated with loss of vibration and position sense, and can progress to severe weakness, spasticity, clonus, paraplegia, and even fecal and urinary incontinence 7-11).

Many cases of clinical syndromes similar to our patient’s initial presentation following recreational abuse of N2O have been reported in the literature4,5,8,11).
As neurologic symptoms can occur prior to the development of the hematologic abnormalities of vitamin B12 deficiency, early recognition of the clinical symptoms and rapid initiation of treatment are essential to prevent progression and ameliorate clinical symptoms. Although most case series show promising outcomes after vitamin B12 replacement, significant improvements may be delayed and are often incomplete in patients with severe symptoms or those in whom treatment has been delayed. In our case, vitamin B12 replacement was started 2 days after admission, because of delays due to laboratory and electromyographic examinations and a suspicious differential diagnosis of thoracic AVM. We performed follow-up MRI 2 days after the initial MRI scan, as the patient showed rapidly progressing weakness in his lower extremities, and found more extended high signal intensity on T2-weighted images. We therefore recommend starting vitamin B12 replacement as early as possible in cases of clinically suspected N2O-induced myelopathy. A thorough diagnostic evaluation utilizing diagnostic blood tests, electrodiagnostic examinations, and imaging is needed for correct diagnosis and proper management. While low serum cobalamin levels may be the only information needed to confirm the diagnosis, borderline or normal levels may occur. Normal vitamin B12 levels do not rule out the possibility of N2O-induced SCD of the spinal cord, given that functional B12 deficiency can occur in the presence of normal serum vitamin B12 levels. In such patients, serum and urine homocysteine and methylmalonic acid metabolites can be used to confirm the diagnosis. MRI findings are characterized by edema secondary to demyelination and eventual gliosis resulting in increased T2 signals in the dorsal and, to a lesser extent, lateral and anterior columns of the spinal cord. A modest expansion of the spinal cord can be seen, and contrast enhancement is rare.

A differential diagnoses of abnormal signal lesions in the posterior columns of the spinal cord include transverse myelitis, lymphoma and other neoplasms, paraneoplastic myelopathy, multiple sclerosis, sarcoidosis, arterial or venous ischemia, and vascular malformations of the dura and spinal cord. In our case, initial MRI revealed suspicious thoracic vascular malformations (Fig. 3); however, diagnostic angiography findings were normal.

In summary, N2O has recently gained popularity at parties in nightclubs and at music festivals in the Republic of Korea, due to its free availability, in the form of “whippets”, aerosol canisters commonly used for whipped cream, each containing 8 g of N2O (Fig. 1), and its low cost. Inhalant abuse of N2O is increasing in the Republic of Korea, similar to the United States and Europe, and clinical suspicions should be high, especially in young patients presenting with myelopathic symptoms of unclear etiology, since this represents a treatable and potentially reversible cause of myelopathy. We also think that public health systems should take a strong stance on restricting the drug’s availability.

REFERENCES

1. Jay M. The atmosphere of heaven: The 1799 nitrous oxide research reconsidered. Notes Rec R Soc Lond. Sep; 63(3):297-309, 2009
2. Global Drugs Survey, London, UK.  http://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf. Accessed. 26 Feb; 2018.
3. Kaar SJ, Ferris J, Waldron J, Devaney M, Ramsey J, Winstock AR. Up: The rise of nitrous oxide abuse. An international survey of contemporary nitrous oxide use. Journal of Psychopharmacology 30(4):395-401, 2016
4. Sethi NK, Mullin P, Torgovnick J, Capasso G. Nitrous oxide “whippit” abuse presenting with cobalamin responsive psychosis. J Med Toxicol. Jun; 2(2):71-74, 2006
5. Thompson AG, Leite MI, Lunn MP, Bennett DL. Whippits, nitrous oxide and the dangers of legal highs. Pract Neurol Jun 15(3):207-209, 2015
6. Lassen HC, Henriksen E, Neurkirch F, Kristensen HS. Treatment of tetanus; Severe bone-marrow depression after prolonged nitrous oxide anaesthesia. Lancet. Apr; 270(6922):527-530, 1956
7. Alt RS, Morrissey RP, Gang MA, Hoffman RS, Schaumburg HH. Severe myeloneuropathy from acute high-dose nitrous oxide (N2O) abuse. J Emerg Med. Oct; 41(4):378-380, 2011
8. Cheng HM, Park JH, Herschtis D. Subacute combined degeneration of the spinal cord following recreational nitrous oxide use. BMJ Case Rep. Mar; 8:2013, 2013
9. Karantanas AH, Markonis A, Bishyianis G. Subacute combined degeneration of the spinal cord with involvement of the anterior columns: A new MRI finding. Neuroradiology. Feb 42(2):115-117, 2000

Fig. 3. T2-weighted sagittal (A) and axial image (B, C) showing engorged vascular lesions around thoracic cord, and diagnostic angiography with normal findings.
10. Stabler SP. Vitamin B12 deficiency. *N Engl J Med.* May 368(21): 2041-2042, 2013

11. Waclawik AJ, Luzzio CC, Juhaz-Pocsine K, Hamilton V. Myeloneuropathy from nitrous oxide abuse: unusually high methylmalonic acid and homocysteine levels. *WMJ* 102(4):43-45, 2003

12. Goodman BP. Metabolic and toxic causes of myelopathy. *Continuum (Minneap Minn).* Feb; 21(1 Spinal Cord Disorders): 84-99, 2015

13. Layzer RB. Myeloneuropathy after prolonged exposure to nitrous oxide. *Lancet.* Dec; 9 2(8102):1227-1230, 1978

14. Ilniczky S, Jelencsik I, Kenex J, Szirmai I. MR findings in subacute combined degeneration of the spinal cord caused by nitrous oxide anaesthesia--two cases. *Eur J Neurol.* Jan; 9(1):101-104, 2002

15. Ravina B, Loevner LA, Bank W. MR findings in subacute combined degeneration of the spinal cord: A case of reversible cervical myelopathy. *AJR Am J Roentgenol.* Mar; 174(3):863-865, 2000

16. Byun JS, Tsang ACO, Hilditch CA, et al. Presentation and outcomes of patients with thoracic and lumbosacral spinal epidural arteriovenous fistulas: A systematic review and meta-analysis. *J Neurointerv Surg.* Aug, 30, 2018.

17. Nasr DM, Brinjikji W, Clarke MJ, Lanzino G. Clinical presentation and treatment outcomes of spinal epidural arteriovenous fistulas. *J Neurosurg Spine.* May 26(5):613-620, 2017